FNDX vs IBB
Schwab Fundamental US Large Company Index ETF vs iShares Biotechnology ETF
- • FNDX has the lower expense ratio at 0.25% vs 0.44% for IBB.
- • FNDX pays a higher dividend yield (1.50%).
Side-by-side metrics
| Metric | FNDX | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.50% | 0.23% |
AUM Assets under management — bigger funds are typically more liquid. | $25.91B | $7.95B |
YTD return | 12.17% | 3.10% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 0.74 |
P/E ratio | 20.94 | 23.72 |
Last price | $30.16 | $170.10 |
Inception | — | — |
Issuer | Schwab | iShares |
FNDX top holdings
| AAPL | Apple Inc | 4.18% |
| XOM | Exxon Mobil Corp | 2.54% |
| MSFT | Microsoft Corp | 2.28% |
| GOOGL | Alphabet Inc Class A | 2.28% |
| INTC | Intel Corp | 2.21% |
| AMZN | Amazon.com Inc | 1.88% |
| GOOG | Alphabet Inc Class C | 1.82% |
| CVX | Chevron Corp | 1.63% |
| JPM | JPMorgan Chase & Co | 1.49% |
| BRK-B | Berkshire Hathaway Inc Class B | 1.47% |
IBB top holdings
| AMGN | Amgen Inc | 7.37% |
| GILD | Gilead Sciences Inc | 7.32% |
| VRTX | Vertex Pharmaceuticals Inc | 7.21% |
| REGN | Regeneron Pharmaceuticals Inc | 6.55% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.71% |
| ARGX | argenx SE ADR | 3.33% |
| INSM | Insmed Inc | 2.70% |
| BIIB | Biogen Inc | 2.67% |
| NTRA | Natera Inc | 2.40% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.27% |
About FNDX
FNDX (Schwab Fundamental US Large Company Index ETF) is US large caps weighted by fundamental factors. Managed by Schwab, the fund carries $25.9B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.50%. Its largest holding is Apple Inc (AAPL), which represents 4.2% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.